SCHEMBL6461798

SCHEMBL6461798

CN1CCN([C@H]2CC[C@H](n3cc(-c4ccc(NS(=O)(=O)c5cccc(Cl)c5Cl)c(F)c4)c4c(N)ncnc43)CC2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 2/20 0.64
EIF2AK3 Q9NZJ5 6/20 0.55
EGFR P00533 3/20 0.55
ERBB2 P04626 3/20 0.55
ERBB4 Q15303 3/20 0.55
IGF1R P08069 2/20 0.55
ERBB3 P21860 2/20 0.55
PLK4 O00444 1/20 0.52
DCLK1 O15075 1/20 0.52
PDPK1 O15530 1/20 0.52
PRKD3 O94806 1/20 0.52
MAP4K4 O95819 1/20 0.52
PAK4 O96013 1/20 0.52
CHEK2 O96017 1/20 0.52
ABL1 P00519 1/20 0.52
NTRK1 P04629 1/20 0.52
INSR P06213 1/20 0.52
LCK P06239 1/20 0.52
FYN P06241 1/20 0.52
CSF1R P07333 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14183076 1.00 TEK (0.64) TEKEIF2AK3EGFRERBB2ERBB4
SCHEMBL30527006 1.00 TEK (0.64) TEKEIF2AK3EGFRERBB2ERBB4
SCHEMBL6461797 1.00 TEK (0.64) TEKEIF2AK3EGFRERBB2ERBB4
SCHEMBL6460184 0.94 TEK (0.67) TEKEIF2AK3EGFRERBB2ERBB4
SCHEMBL6465003 0.94 TEK (0.63) TEKEIF2AK3EGFRERBB2ERBB4
SCHEMBL6463702 0.94 TEK (0.62) TEKEIF2AK3EGFRERBB2ERBB4
SCHEMBL6465261 0.92 TEK (0.66) TEKEIF2AK3EGFRERBB2ERBB4
SCHEMBL6462812 0.91 TEK (0.70) TEKEIF2AK3EGFRERBB2ERBB4
SCHEMBL2074338 0.90 EIF2AK3 (0.53) TEKEIF2AK3EGFRERBB2ERBB4
SCHEMBL6460003 0.90 TEK (0.63) TEKEIF2AK3EGFRERBB2ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 US disclosed
US-6713474-B2 SERINE-THREONINE AND TYROSINE KINASE INHIBITORS ABBOTT GMBH & CO. KG (DE) 2004-03-30 US disclosed
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN TEK 1465/4885EIF2AK3 3756/4885EGFR 818/4885
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents FLT1, FLT4, TFPI TEK 22/4885EIF2AK3 928/4885EGFR 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.